title: Lung adenocarcinoma invasion in TGFbetaRII-deficient cells is mediated by CCL5/RANTES.
abstract: Recently, we identified a lung adenocarcinoma signature that segregated tumors into three clades distinguished by histological invasiveness. Among the genes differentially expressed was the type II transforming growth factor-beta receptor (TGFbetaRII), which was lower in adenocarcinoma mixed subtype and solid invasive subtype tumors compared with bronchioloalveolar carcinoma. We used a tumor cell invasion system to identify the chemokine CCL5 (RANTES, regulated on activation, normal T-cell expressed and presumably secreted) as a potential downstream mediator of TGF-beta signaling important for lung adenocarcinoma invasion. We specifically hypothesized that RANTES is required for lung cancer invasion and progression in TGFbetaRII-repressed cells. We examined invasion in TGFbetaRII-deficient cells treated with two inhibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody. Both treatments blocked invasion induced by TGFbetaRII knockdown. In addition, we examined the clinical relevance of the RANTES-CCR5 pathway by establishing an association of RANTES and CCR5 immunostaining with invasion and outcome in human lung adenocarcinoma specimens. Moderate or high expression of both RANTES and CCR5 was associated with an increased risk for death, P=0.014 and 0.002, respectively. In conclusion, our studies indicate RANTES signaling is required for invasion in TGFbetaRII-deficient cells and suggest a role for CCR5 inhibition in lung adenocarcinoma prevention and treatment.
authors.affiliation: Department of Pathology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: A C
authors.initials: AC
authors.lastname: Borczuk
authors.forename: N
authors.initials: N
authors.lastname: Papanikolaou
authors.forename: R L
authors.initials: RL
authors.lastname: Toonkel
authors.forename: M
authors.initials: M
authors.lastname: Sole
authors.forename: L A
authors.initials: LA
authors.lastname: Gorenstein
authors.forename: M E
authors.initials: ME
authors.lastname: Ginsburg
authors.forename: J R
authors.initials: JR
authors.lastname: Sonett
authors.forename: R A
authors.initials: RA
authors.lastname: Friedman
authors.forename: C A
authors.initials: CA
authors.lastname: Powell
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D018946:Chemokine CCL5 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015331:Cohort Studies; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D009361:Neoplasm Invasiveness; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D000077294:Receptor, Transforming Growth Factor-beta Type II; D019713:Receptors, CCR5 / Q000235:genetics / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology; D016019:Survival Analysis; D014407:Tumor Cells, Cultured
chemical_list: D018946:Chemokine CCL5; D019713:Receptors, CCR5; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II